immunitoAI
Category: AI in Healthcare
immunitoAI is a TechBio company developing AI-generated novel antibody therapeutics with pre-defined drug properties, leveraging AI to accelerate antibody discovery and drug development. immunitoAI was founded in 2020. The company is led by Aridni Shah. Based in Bengaluru, India. Team size: 10-50. Total funding raised: $7.1M. Latest round: Series A. Key investors include pi Ventures, Ashish Kacholia, 3one4 Capital, AC Ventures, Anicut Capital, JITO Incubation & Innovation Foundation.
- Founded
- 2020
- Headquarters
- Bengaluru, India
- Team size
- 10-50
- Total funding
- $7.1M
Value proposition
Reduces antibody development time from 4-5 years to 11-12 months using AI, enabling faster drug discovery with pre-defined therapeutic properties.
Products and solutions
AI-driven antibody discovery platform, imRANK (antibody binding prediction tool), Customizable antibody therapeutics for targeted drug delivery
Unique value
AI-generated antibody design with pre-defined properties, combining deep learning and immunoassay expertise for precision drug discovery.
Target customer
Pharmaceutical companies, biotechnology firms, and healthcare providers seeking advanced antibody-based therapies for diseases like cancer, autoimmune disorders, and infectious diseases.
Industries served
Healthcare, Biotechnology, Pharmaceuticals, AI-driven Drug Discovery
Technology advantage
Proprietary AI algorithms trained on extensive biological data, enabling rapid virtual screening and design of high-affinity antibodies.
How they differentiate
immunitoAI differentiates through its de novo AI-generated antibody design platform, reducing development time from 4-5 years to 11-12 months. Unlike competitors relying on biological screening, it uses AI to create antibodies from scratch with pre-defined drug properties.
Main competitors
Antiverse, Nabla Bio, Helixon, Generate Biomedicines, Chai2, Immunai
Key partnerships
Entrepreneur First (incubation and early-stage support), Google Cloud (collaboration in AI infrastructure), Brio Technologies (AI Roadshow and healthcare innovation partnerships), Intel Corporation (cooperation in AI Open Innovation initiatives)
Major milestones
Raised $6.1M in 2025 Series A funding, Built AI platform reducing antibody development time by 75%, Recognized at Intel AI Open Innovation Day 2023, Launched first AI-generated antibody pipeline in 2022
Growth metrics
Pre-revenue; 10-50 employees; platform in active development with no public clinical trial data yet.
Market positioning
Positioned as a challenger in AI-driven antibody therapeutics, focusing on cost-effective and rapid drug discovery for oncology and autoimmune diseases. Competes with global players while addressing the Indian biotech market's underserved needs.
Geographic focus
Headquartered in Bengaluru, India, with market focus on Asia-Pacific. Expanding globally through partnerships and investor networks (e.g., Ashish Kacholia's international connections).
Patents and IP
No publicly disclosed patents identified in recent sources (2024-2025), though the company is in the process of protecting its intellectual property through patent applications.
About Aridni Shah
PhD in Biological Sciences from National Centre of Biological Sciences (NCBS), TIFR; 10+ years of experience in immunoassays, molecular techniques & data analytics; Former Founder in Residence at Entrepreneur First; Publications in 3 international journals with participation in 8 global conferences
Official website: https://www.immunitoai.com